WASHINGTON (Reuters) - Certain contrast agents used in magnetic resonance imaging -- gadolinium-based products made by Bayer AG, GE and others -- will now carry the U.S. Food and Drug Administration's strongest, "black box" warning.
The FDA's move on Friday finalizes its announcement in May that it would add the labeling warning to the MRI contrast agents.
